Abstract 1736P
Background
Young adult lung cancer's socioeconomic and clinical implications make it a unique disease. However, in Bangladesh, the status and features of early-onset lung cancer are not well understood. This study aimed to investigate the socio-demographic status and clinical characteristics of lung cancer in young adults in Bangladesh.
Methods
A retrospective review of patients with lung cancer was performed in our institute from January 2018 and December 2022. Young adults were defined as individuals between 18 and 45 years old. Demographic, clinicopathological and prognostic data were systematically analysed.
Results
Of the 6310 patients, 819 (12.98%) were young adults, and 780 were included in this study. The average age of young adult lung cancer patients was 38.92 years, and the average BMI was 20.46. Of all adult lung cancer patients, 29.49% were female, 58.97% were illiterate, and 87.56% had poor or below-average economic status. Among young adults, 23.08% did not use tobacco, while 41.41% had more than one tobacco-related habit. 33.52% of young patients with right-sided dominant lung cancer had a previous respiratory disease. At the time of presentation, 43.85% of patients had a score of ≥2 on the ECOG scale, and 33.52% had comorbidities, with hypertension being the most frequent (37.36%) and DM (33%) being the second most common. Adenocarcinoma was the most prevalent subtype (58.97%), followed by squamous (24.74%), small cell varieties with undifferentiated (14.74%), and others like sarcoma and mesothelioma. Stage 4 was diagnosed in 28.46% of patients, and the most frequent metastatic site was the lung (14.42%), followed by the pleura (12.5%) and the liver (11.06%). Young lung cancer patients in Bangladesh significantly differed from older adults regarding higher BMI, lower education, more female patients, fewer tobacco users, adenocarcinoma, and different metastatic sites (p 0.05).
Conclusions
The high prevalence of young adult lung cancer in Bangladesh necessitates specialized attention to this vulnerable group during treatment. These patients face unique challenges, making the management of their cancer complex and resulting in poor outcomes. A personalized and comprehensive approach is essential to manage young lung cancer effectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23